Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANY Sphere 3D	$0.53 -6.9%	$0.62	$0.36 ▼ $1.90	$14.91M	3.22	637,684 shs	629,302 shs
BTCT BTC Digital	$2.49 -3.5%	$3.08	$1.32 ▼ $26.58	$18.72M	5.05	1.19 million shs	166,745 shs
GREE Greenidge Generation	$1.39 -6.7%	$1.54	$0.58 ▼ $3.84	$21.46M	3.14	293,936 shs	117,765 shs
NRBO NeuroBo Pharmaceuticals	$0.65 +1.7%	$0.67	$2.08 ▼ $4.41	$5.61M	-0.26	39,605 shs	85,989 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANY Sphere 3D	-2.47%	+12.04%	-14.97%	-37.97%	-32.55%
BTCT BTC Digital	+5.31%	-2.27%	-23.21%	-35.82%	+67.53%
GREE Greenidge Generation	+2.05%	+10.37%	-23.59%	+18.25%	-19.02%
NRBO NeuroBo Pharmaceuticals	0.00%	+1.60%	-5.03%	-8.44%	-82.51%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANY Sphere 3D	3.2515 of 5 stars	3.5	5.0	0.0	0.0	4.0	0.0	0.6
BTCT BTC Digital	1.2413 of 5 stars	0.0	4.0	0.0	0.0	2.8	0.0	1.3
GREE Greenidge Generation	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NRBO NeuroBo Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANY Sphere 3D	3.00	Buy	$3.00	469.91% Upside
BTCT BTC Digital	0.00	N/A	N/A	N/A
GREE Greenidge Generation	0.00	N/A	N/A	N/A
NRBO NeuroBo Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest NRBO, GREE, BTCT, and ANY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
5/21/2025	ANY Sphere 3D	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00 ➝ $3.00

(Data available from 8/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANY Sphere 3D	$10.83M	1.38	N/A	N/A	$1.54 per share	0.34
BTCT BTC Digital	$11.68M	1.60	$0.27 per share	9.37	$6.20 per share	0.40
GREE Greenidge Generation	$59.53M	0.36	N/A	N/A	($4.28) per share	-0.32
NRBO NeuroBo Pharmaceuticals	N/A	N/A	N/A	N/A	$1.50 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANY Sphere 3D	-$9.47M	-$0.61	N/A	N/A	N/A	-131.43%	-47.27%	-41.94%	N/A
BTCT BTC Digital	-$1.99M	N/A	0.00	N/A	N/A	-24.34%	-9.68%	-8.40%	8/20/2025 (Estimated)
GREE Greenidge Generation	-$19.78M	N/A	0.00	∞	N/A	-33.68%	N/A	-34.08%	N/A
NRBO NeuroBo Pharmaceuticals	-$12.47M	N/A	0.00	N/A	N/A	N/A	-189.12%	-122.31%	11/5/2025 (Estimated)

Latest NRBO, GREE, BTCT, and ANY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/13/2025	Q2 2025	GREE Greenidge Generation	-$0.44	-$0.27	+$0.17	-$0.27	$14.30 million	$12.90 million
8/5/2025	Q2 2025	ANY Sphere 3D	-$0.11	-$0.10	+$0.01	$0.06	$4.60 million	$3.02 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANY Sphere 3D	N/A	N/A	N/A	N/A	N/A
BTCT BTC Digital	N/A	N/A	N/A	N/A	N/A
GREE Greenidge Generation	N/A	N/A	N/A	N/A	N/A
NRBO NeuroBo Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANY Sphere 3D	N/A	6.69	6.69
BTCT BTC Digital	0.01	27.50	27.49
GREE Greenidge Generation	N/A	1.05	1.05
NRBO NeuroBo Pharmaceuticals	N/A	2.41	2.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANY Sphere 3D	17.28%
BTCT BTC Digital	7.32%
GREE Greenidge Generation	8.50%
NRBO NeuroBo Pharmaceuticals	1.37%

Insider Ownership

Company	Insider Ownership
ANY Sphere 3D	3.60%
BTCT BTC Digital	0.22%
GREE Greenidge Generation	27.80%
NRBO NeuroBo Pharmaceuticals	1.05%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANY Sphere 3D	20	28.32 million	27.30 million	Optionable
BTCT BTC Digital	16	7.52 million	7.50 million	Not Optionable
GREE Greenidge Generation	680	15.44 million	11.15 million	No Data
NRBO NeuroBo Pharmaceuticals	10	8.62 million	8.53 million	Not Optionable

NRBO, GREE, BTCT, and ANY Headlines

Recent News About These Companies

MTVA: NeuroBo Becomes MetaVia; Topline Results for Phase 2a Trial of DA-1241 in MASH Expected in December 2024…

December 4, 2024 | msn.com

NeuroBo Pharmaceuticals Rebrands as MetaVia: Strategic Positioning and Growth Potential Highlighted in Buy Rating by Jason McCarthy

November 21, 2024 | markets.businessinsider.com

NeuroBo Pharmaceuticals rebrands to become MetaVia

November 19, 2024 | fiercepharma.comF

NeuroBo Pharmaceuticals Rebrands Amidst Strategic Changes

November 19, 2024 | markets.businessinsider.com

NeuroBo Pharmaceuticals announces relignment, change name

November 19, 2024 | markets.businessinsider.com

NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic Diseases

November 18, 2024 | prnewswire.com

NRBO: Topline Results for Phase 2a Trial of DA-1241 in MASH Expected in December 2024

November 13, 2024 | msn.com

NeuroBo Pharmaceuticals to Participate in Investor Conferences in November

November 13, 2024 | prnewswire.com

NeuroBo Pharmaceuticals to Present at the November 21st Virtual Investor Summit Microcap Event

November 12, 2024 | bignewsnetwork.comB

NeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update

November 7, 2024 | prnewswire.com

NeuroBo Pharmaceuticals Completes Last Patient Last Visit in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

November 4, 2024 | prnewswire.com

NeuroBo Pharmaceuticals (NASDAQ:NRBO) Stock Quotes, Forecast and News Summary

October 4, 2024 | benzinga.com

NRBO: Positive SAD Part 1 Data; MAD Part 2 Results Expected in 1Q25…

October 1, 2024 | msn.com

NeuroBo Pharmaceuticals to Participate in Investor Conferences in October

October 1, 2024 | prnewswire.com

NeuroBo Pharma Announces Positive Results From Phase 1 Trial Of DA-1726 In Obesity Treatment

September 30, 2024 | markets.businessinsider.com

We're A Little Worried About NeuroBo Pharmaceuticals' (NASDAQ:NRBO) Cash Burn Rate

September 30, 2024 | finance.yahoo.com

NeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

September 30, 2024 | prnewswire.com

NeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

September 3, 2024 | prnewswire.com

NRBO: Data from Part 1 of Phase 1 Trial of DA-1726 in 3Q24…

August 21, 2024 | msn.com

Buy Rating for NeuroBo Pharmaceuticals Based on Financial Stability and Promising Developmental Pipeline

August 16, 2024 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

NRBO, GREE, BTCT, and ANY Company Descriptions

Sphere 3D NASDAQ:ANY

$0.53 -0.04 (-6.93%)

Closing price 04:00 PM Eastern

Extended Trading

$0.52 -0.01 (-1.41%)

As of 06:49 PM Eastern

Sphere 3D Corp. engages in the bitcoin mining business. It is involved with digital asset mining pool operators to provide computing power to the mining pools. The company is based in Stamford, Connecticut.

BTC Digital NASDAQ:BTCT

$2.49 -0.09 (-3.49%)

Closing price 04:00 PM Eastern

Extended Trading

$2.52 +0.03 (+1.04%)

As of 06:22 PM Eastern

BTC Digital Ltd. a crypto asset technology company engages in bitcoin mining business. It is also involved in mining machines resale and rental business. The company was formerly known as Meten Holding Group Ltd. and changed its name to BTC Digital Ltd. in August 2023. The company was founded in 2006 and is headquartered in Shenzhen, China.

Greenidge Generation NASDAQ:GREE

$1.39 -0.10 (-6.71%)

Closing price 04:00 PM Eastern

Extended Trading

$1.38 0.00 (-0.36%)

As of 06:58 PM Eastern

Greenidge Generation Holdings Inc. operates as an integrated cryptocurrency datacenter and power generation company. The company owns and operates cryptocurrency datacenter in New York, as well as hosts, powers, and provides technical support and other related services to bitcoin mining equipment owned by customers. It also owns and operates a 106 MW nameplate capacity power generation facility. The company was founded in 1937 and is based in Fairfield, Connecticut.

NeuroBo Pharmaceuticals NASDAQ:NRBO

$0.65 +0.01 (+1.66%)

As of 08/18/2025

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene. NeuroBo Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time